Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 257Carcinoma, Intraductal, Noninfiltrating 24Breast Carcinoma In Situ 21Neoplasms 12Neoplasm Metastasis 12Breast Neoplasms, Male 12Ovarian Neoplasms 10Inflammatory Breast Neoplasms 7Glioblastoma 6Prostatic Neoplasms 5Endometrial Neoplasms 5Central Nervous System Neoplasms 5Gliosarcoma 4Fallopian Tube Neoplasms 4Breast Cancer Female 4Brain Neoplasms 4Glioma 3Carcinoma, Ovarian Epithelial 3Carcinoma, Ductal, Breast 3Breast Diseases 3Astrocytoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma 2Recurrence 2Pancreatic Neoplasms 2Oligodendroglioma 2Medulloblastoma 2Liver Neoplasms 2Infertility 2

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Letrozole 2exemestane 1eribulin 1dalpiciclib 1Tamoxifen 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HR Positive HER2 Negative Advanced Breast Cancer × Tamoxifen × Clear all
NCT05890287 2023-06-06

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
60 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡